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ABSTRACT 
Adult onset neuronal lipofuscinosis (ANCL) is a human neurodegenerative disorder 
characterised by progressive neuronal dysfunction and premature death. Recently, the 
mutations that cause ANCL were mapped to the DNAJC5 gene, which encodes cysteine 
string protein alpha. We show here that mutating dnj-14, the Caenorhabditis elegans 
orthologue of DNAJC5, results in shortened lifespan and a small impairment of 
locomotion and neurotransmission. Mutant dnj-14 worms also exhibited age-dependent 
neurodegeneration of sensory neurons, which was preceded by severe progressive 
chemosensory defects. A focused chemical screen revealed that resveratrol could 
ameliorate dnj-14 mutant phenotypes, an effect mimicked by the cAMP 
phosphodiesterase inhibitor, rolipram. In contrast to other worm neurodegeneration 
models, activation of the Sirtuin, SIR-2.1, was not required, as sir-2.1; dnj-14 double 
mutants showed full lifespan rescue by resveratrol. The Sirtuin-independent 
neuroprotective action of resveratrol revealed here suggests potential therapeutic 
applications for ANCL and possibly other human neurodegenerative diseases. 
 3 
INTRODUCTION 
Age-related neurodegenerative diseases have a devastating impact on affected 
individuals and pose a significant economic challenge for society. There is a pressing 
need to identify molecular and cellular neuroprotective mechanisms that decline with 
ageing so that drugs can be developed to modulate the neurodegenerative process and 
hence extend health-span. Human genetic studies have successfully identified single 
gene mutations in various neurodegenerative disorders. For example, frontotemporal 
dementia, Parkinson’s and Huntington’s diseases are associated with alterations in genes 
encoding tau, α-synuclein and huntingtin, respectively (1). Because misfolding and 
aggregation of these and other proteins is associated with disease progression, it is 
thought that defective protein homeostasis is a common underlying feature of 
neurodegeneration (2). Indeed, studies in animal models using genetic or 
pharmacological approaches have shown that altering the activity of molecular 
chaperones, proteasomes and autophagy can be neuroprotective (2-5). Drugs targeting 
these processes therefore represent promising candidate therapies. 
  Adult onset neuronal lipofuscinosis (ANCL), also known as autosomal dominant 
Kufs disease and Parry disease, is a hereditary neurodegenerative disorder (6). There is 
broad clinical variability, but common signs include generalised epilepsy, movement 
disorders and progressive dementia. The disease has a mean age of onset of 30 years and 
progresses rapidly, with death occurring on average at 45 years of age (7). 
Pathologically, ANCL is associated with intra-neuronal inclusions and 
neurodegeneration. Recently, several independent groups have discovered that ANCL is 
caused by mutations in the DNAJC5 gene (7-10).  
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DNAJC5 encodes an evolutionarily conserved member of the DnaJ/Hsp40 family 
of molecular chaperones known as cysteine string protein (CSP) (11, 12). Its name 
derives from the possession of a motif containing 12-14 cysteine residues, 
palmitoylation of which is required for targeting of CSP to synaptic vesicles (13). ANCL 
patients all harbour mutations in DNAJC5 that cause substitution or deletion of a pair of 
leucine residues within this cysteine string motif. These are effectively functionally null 
alleles, as the mutations have been shown to greatly reduce synaptic CSP levels and to 
phenocopy other DNAJC5 loss-of-function mutants (8, 14, 15). Mouse dnajc5 null 
mutants are characterised by age-dependent sensorimotor dysfunction, 
neurodegeneration and premature mortality, and exhibit synthetic genetic interactions 
with α-synuclein (16, 17). It is thought that CSP acts as a specialised synaptic molecular 
chaperone, maintaining SNAP-25 in a conformation competent for entry into the 
fusogenic SNARE complex (18-20), although re-folding of other client proteins such as 
dynamin 1 is also likely to play a role (21). In DNAJC5 mutants, the loss of this synaptic 
chaperone activity is thought to lead to neurodegeneration. 
Caenorhabditis elegans has been used to model various neurodegenerative 
diseases, mainly by overexpressing human genes containing disease-associated 
mutations (22, 23). Although some common genetic modifiers have been identified 
among these models, many of the underlying cellular mechanisms affected appear to be 
disease-specific, despite the shared feature of protein misfolding/aggregation (3, 24). In 
order to identify generally neuroprotective interventions, an alternative approach is to 
search for compounds that are able to compensate for the loss of an endogenous 
physiological neuroprotective factor (25).  Here we describe such a model, using C. 
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elegans containing loss of function mutations in dnj-14 (the worm orthologue of the 
DNAJC5 gene mutated in ANCL); and demonstrate its potential for chemical genetic 
screening, by identifying a sir-2.1-independent neuroprotective effect of resveratrol.  
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RESULTS 
Phenotypic consequences of impaired dnj-14 function 
The C. elegans genome encodes a single homologue of the DNAJC5 gene that is mutated 
in ANCL: dnj-14. A comparison of the human and worm predicted proteins reveals 
extensive sequence similarity in the J domain and central cysteine string region, with 
more divergence evident in the C-termini (Fig. S1A). To determine if this structural 
similarity extends to function, we characterised a mutant strain (ok237 allele), which 
contains a 2229-bp deletion that eliminates the majority of the dnj-14 (KO2G10.8) 
coding region and its putative promoter (Fig S1B,C). dnj-14(ok237) worms were viable 
and fertile, although they produced less progeny and development from egg to adult was 
slower than wild type N2 control worms. Once developed into young adults, dnj-
14(ok237) worms were superficially normal, as evidenced by their locomotion behaviour 
on agar plates (Movie S1).  
As mutations in DNAJC5 homologues are associated with reduced lifespan in 
humans (7-10), mice (16) and flies (11), we performed lifespan analysis on dnj-14(ok237) 
and wild type N2 worms. In each of 7 independent experiments performed by multiple 
individuals, dnj-14(ok237) mutants exhibited shorter lifespan than wild type N2 worms. 
Similar results were seen whether FUDR (to prevent progeny development) was included 
in the NGM plates or omitted. Over this series, the mean lifespan of the dnj-14(ok237) 
strain was 13.3 days (95% CI: 12.8-13.8) compared to 18.7 days (95% CI: 18.2-19.2) for 
the wild type N2 strain (Fig. 1A). We therefore conclude that deletion of dnj-14 causes a 
reproducible and significant lifespan reduction. 
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 Although dnj-14(ok237) worms exhibited superficially normal movement on agar 
plates (Movie S1), quantification of locomotion in solution revealed a small, but 
significant, reduction in thrashing activity (Fig. 1B) that became more pronounced with 
ageing. To determine if the impairment of locomotion was associated with a reduction in 
neurotransmitter release, we assayed the time taken for paralysis to be induced by the 
acetylcholinesterase inhibitor, aldicarb using established procedures (26). There was no 
significant difference in aldicarb assays between wild type and mutant 1-day old worms 
(Fig. 1C), but older dnj-14 mutants displayed a significant delay in the time taken to 
become paralysed (Fig. 1D). This rightward shift in the curve is indicative of a Ric 
(resistance to inhibitors of cholinesterase) phenotype, suggesting that dnj-14 mutants 
exhibit a progressive, minor impairment of neurotransmitter release. The reduced lifespan 
of the ok237 strain persisted despite back-crossing 6 times with the N2 control strain 
(Fig. 1E) and could be significantly increased by transgenic expression of dnj-14 under 
the control of its putative natural promoter (Fig. 1F).  
In addition to deleting dnj-14, the ok237 allele also extends into the adjacent glit-1 
gene (Fig. S1B), raising the possibility that the observed phenotypes may be due to 
effects on glit-1 rather than dnj-14. To rule this out, we obtained a second allele, tm3223, 
where the mutation was confined to dnj-14 alone. Genomic DNA from the dnj-
14(tm3223) strain was prepared and the dnj-14 gene was PCR amplified and sequenced, 
revealing a 233 bp deletion and an insertion of 5 adenines within exon 2 of dnj-14. This 
would be predicted to produce a truncated protein terminating immediately after the J 
domain of DNJ-14. Over a series of 4 independent experiments performed by multiple 
individuals, dnj-14(tm3223) mutants consistently exhibited shorter lifespan than wild 
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type N2 worms, the mean lifespan of the tm3223 strain being 14.0 days (95% CI: 13.46-
14.44) compared to 18.3 days (95% CI: 17.5-19.1) for the N2 strain (Fig. 2A). We also 
found that dnj-14(tm3223) mutants displayed reduced locomotion in thrashing assays 
(Fig. 2B) and impaired neurotransmission in aldicarb assays (Fig. 2C), thus 
phenocopying the dnj-14(ok237) strain. To further confirm that these phenotypes were 
due to impairment of DNJ-14 function, we knocked down dnj-14 expression using the 
RNAi-sensitive eri-1 strain (27). This resulted in a lifespan reduction of similar 
magnitude to that seen with the ok237 and tm3223 alleles (Fig. 2D). Knockdown of dnj-
14 also recapitulated the small decrease in thrashing observed in the mutant strains (Fig. 
2E). Although the control eri-1 strain showed a much more severe reduction in 
locomotion during ageing than the N2 control strain, dnj-14 RNAi exacerbated this 
further (Fig. 2E), consistent with results from the mutant strains. Confirmation that the 
RNAi vector used did indeed reduce the levels of dnj-14 gene expression was provided 
via RT-PCR (Fig. 2F).  
 
Sensory neurons are impaired in dnj-14 mutants 
Having established that the phenotype of the ok237 strain is due to loss of dnj-14 
function, we used this null mutant strain to investigate effects on neurodegeneration, 
which is a feature of ANCL in humans. We employed the well-established approach of 
using free cytoplasmic GFP expressed from a neuron-specific promoter as a marker for 
neuronal viability and morphology, similar to previous studies (28, 29). Live neurons 
were visualised in wild type and dnj-14(ok237) animals by gonadal microinjection of a 
plasmid encoding GFP driven by the pan-neuronal rab-3 promoter. As can be seen in Fig. 
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3A, this results in labelling of all neuronal cell bodies and neurites in the worm, with 
neurons in the head, the nerve ring and the nerve cords being most apparent. There was 
no discernible difference in GFP labelling between wild type and dnj-14(ok237) worms at 
less than 7 days of age. However, we observed notable neuronal abnormalities in the 
anterior head region of older dnj-14 animals (Fig. 3A, Fig S3). This manifested as a loss 
of neuronal cell bodies, a reduction in the number of visible neurites, or the presence of 
contorted neuronal processes in the head of the worms. In contrast, age-matched wild 
type N2 animals generally exhibited obvious neuronal cell bodies and had clearly labelled 
multiple neurites that extended straight to the end of the worm’s head without twisting. 
We also observed an increase in the proportion of dnj-14 animals with large GFP punctae 
in the dorsal nerve cord (Fig. 3A, Fig S3); however, this phenotype was more variable 
and the difference between wild type and mutant worms less obvious for than for the 
head neuron abnormalities described above. The nature of these punctae is not clear, 
although given that lysosomal inclusions are a feature of ANCL and that GFP 
fluorescence is resistant to lysosomal degradation (30), it is conceivable that they reflect 
accumulations of GFP within lysosomes. To quantify these phenotypes, worms from 9 
days of adulthood and older were imaged and scored for head neuron abnormalities 
(‘neuron loss’) and the presence of dorsal nerve cord GFP aggregates (‘punctae’) (Fig. 
S2). This revealed that around 70% of dnj-14 mutants exhibited alterations in head 
neuron staining compared to only 9% of wild type worms, representing an approximately 
8-fold increase. GFP punctae were evident in around 30% of aged control animals, with 
this proportion increasing to approximately 60% of dnj-14 mutants. We therefore 
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conclude that loss of dnj-14 function results in age-dependent neurodegeneration that 
primarily affects anterior head neurons. 
Given that the C. elegans head is rich in sensory neurons, we reasoned that this 
could affect the animal’s ability to sense and react to environmental cues. 
Mechanosensation, as assayed by touch to both the nose and the side of the head, was no 
different between wild type, dnj-14(tm3223) and dnj-14(ok237) strains at 6-days old (Fig. 
S4). Pharyngeal pumping was similarly unaffected in either allele at 6-days of age (Fig. 
S5), indicating that dnj-14 mutants are neither generally sick nor defective in functions of 
the worm head region. In contrast, dnj-14(tm3223) worms were severely impaired in a 
food race assay, which determines the time taken for animals to move a defined distance 
to a bacterial food source (Fig. 3B). This defect was already evident in young (day 2) 
animals and was progressive, such that most day-6 dnj-14(tm3223) mutants appeared 
unaware of the location of the food source, in contrast to age-matched N2 controls. The 
same phenotype was seen with the dnj-14(ok237) allele and this could be rescued to close 
to control levels by transgenic expression of dnj-14 (Fig. 3C). The observed defect in the 
food race assay was too severe to be explained by the minor locomotor defect in the 
animals, suggesting that a specific effect on chemosensation/olfaction was involved. To 
test this directly, chemotaxis assays using the well-established attractant, isoamyl alcohol, 
were employed (Fig. 3D). These revealed that dnj-14(tm3223) mutants have a severe 
deficiency in detecting and reacting to this volatile attractive compound. Given that 
profound defects in food race and chemotaxis assays were evident in young animals at 
ages where neuronal GFP staining was normal, this suggests that functional impairment 
precedes neurodegeneration in dnj-14 mutants. 
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Screen for compounds that rescue dnj-14 phenotypes identifies resveratrol 
We reasoned that the dnj-14 model could be used to identify compounds with therapeutic 
potential for ANCL and possibly other neurodegenerative diseases. To test this idea, we 
screened a set of compounds for their ability to increase the short lifespan of dnj-14 
mutants. The compounds were chosen based on their reported beneficial effects on 
various different neurodegenerative disease models or on lifespan in wild type worms 
(Table S1). Lifespan assays of wild type and dnj-14(ok237) worms were performed by 
transferring untreated age-synchronised L4-stage animals onto NGM plates containing 
the appropriate compounds or vehicle controls (Fig. 4A). This first screen identified 
several compounds that affected lifespan in dnj-14 mutants. Upon re-testing of these 
compounds in repeat experiments, only resveratrol was found to reproducibly and 
significantly extend lifespan in dnj-14(ok237) worms.  This effect was concentration-
dependent, with 100 µM resveratrol producing maximal lifespan extension (Fig. 4B,C). 
In contrast, resveratrol did not significantly increase lifespan in N2 control worms (Fig. 
4C), suggesting a specific rescue of the defects caused by loss of DNJ-14. Resveratrol 
produced a partial rescue of the neurodegeneration phenotype (Fig. S2); and was also 
able to significantly ameliorate the food race and chemotaxis defects of dnj-14 mutants 
(Fig. 4D,E).  
 
Resveratrol activity is mimicked by phosphodiesterase inhibition and independent 
of SIR-2.1. 
The mechanism of action of resveratrol is unclear and controversial. Recent work has 
suggested that it acts as a cAMP phosphodiesterase (PDE) inhibitor (31), although this 
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has not yet been confirmed by other studies. Consistent with this idea, we found that the 
PDE inhibitor, rolipram, mimicked the ability of resveratrol to rescue the short lifespan 
and sensory defects of dnj-14 mutants (Fig. 5A-C). To directly test if resveratrol and 
rolipram acted via increasing cAMP levels, we performed cAMP assays on lysates from 
worms treated with these drugs for up to two hours. Unfortunately, we did not even see 
an effect of the positive control rolipram (Fig. S6), so it was not possible to draw any 
conclusions from these experiments about the role of cAMP.  Therefore, it remains 
possible that resveratrol and rolipram work through independent mechanisms to rescue 
the dnj-14 mutant phenotypes. Resveratrol is thought to activate (directly or indirectly) 
the Sirtuin class of NAD+-dependent histone deacetylases. Indeed, the effects of 
resveratrol in several C. elegans neurodegeneration models have been shown to be 
dependent on the Sirtuin, sir-2.1 (32-34). We therefore constructed a double mutant dnj-
14;sir-2.1 strain to determine if this was also the case for our ANCL model. The sir-2.1 
mutation caused a small reduction in lifespan in both the wild type and dnj-14 
backgrounds (Fig. 5D), consistent with previous findings. Resveratrol had no significant 
effect on the lifespan of the N2 or sir-2.1 strains (Fig. 5E). Strikingly, the ability of 
resveratrol to increase longevity in the single dnj-14 strain was fully maintained in the 
double mutant dnj-14;sir-2.1 strain (Fig. 5F). This therefore suggests that resveratrol’s 
protective effects are mediated via a sir-2.1-independent mechanism that is distinct from 
previously published worm neurodegeneration models. 
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DISCUSSION 
In this study, we report the phenotypes of C. elegans containing mutations in dnj-14, the 
orthologue of the CSP-encoding DNAJC5 gene that is mutated in ANCL. dnj-14 mutants 
are almost indistinguishable from wild type worms when young, but have a reduced 
lifespan and develop profound sensory neuron defects with increasing age. The latter 
effect shows selectivity for sensory neuron classes, as mechanosensory neurons are 
unaffected at age points when chemosensation is severely impaired, thus ruling out 
general sickness effects. This impaired chemosensory function is already severe by day 5, 
whereas visible abnormalities in sensory neurons are only evident from around 9 days of 
age; hence functional synaptic deficits precede neurodegeneration in our dnj-14 model, 
similar to other neurodegenerative disease models (23). These phenotypes have some 
similarities to ANCL, which is characterised by adult onset (around age 30), short 
lifespan and selectivity in the types of neurons affected - for example, the visual system 
tends to be unaffected in ANCL, unlike other NCLs that are generally associated with 
blindness (6, 7). The worm dnj-14 phenotype is also reminiscent of dnajc5 knockout 
mice, which are indistinguishable from wild type littermates for the first few weeks, but 
have a short lifespan associated with progressive sensorimotor defects and 
neurodegeneration (16). These mice also show selective vulnerability of certain classes of 
neurons, in that hippocampal GABAergic neurons degenerate at time-points where 
glutamatergic transmission is unaffected (35). In contrast, Drosophila csp null mutations 
cause 95% embryonic lethality, with the few flies surviving to adulthood being extremely 
sick and short lived (11, 12). It has been suggested (36) (but disputed (16, 37)) that the 
relatively mild phenotype of mouse dnajc5 mutants may be due to compensatory 
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expression of CSPβ, which is highly homologous to CSPα but not present in Drosophila. 
However, as the worm genome contains only one CSP homologue, it appears more likely 
that the initially mild but progressive, age-dependent phenotypes shared by humans, mice 
and nematodes reflect the conserved functions of CSPα. The extreme severity of fly csp 
mutants coupled with the unfeasibility of performing high throughput screens in mice 
suggests that the worm dnj-14 model may be an attractive new platform for chemical 
genetic screens for neuroprotective factors. 
The focused screen performed here revealed a potent protective effect of 
resveratrol on dnj-14 mutant phenotypes. Resveratrol is a naturally occurring 
polyphenolic compound that has cardioprotective, anti-inflammatory, anti-tumour and 
neuroprotective properties (38). Although various mechanisms of action have been 
proposed, most attention has focused on resveratrol’s ability to activate the Sirtuin class 
of NAD+-dependent histone deacetylases, notably SIRT1. Indeed, various studies have 
shown that resveratrol action is dependent on SIRT1 in mammals and its homologue SIR-
2.1 in C. elegans (32-34, 39, 40). However, whether resveratrol is a direct allosteric 
activator of Sirtuins (40) or instead affects Sirtuins indirectly via competitive inhibition 
of cAMP phosphodiesterases (31) remains controversial. Our finding that resveratrol’s 
rescue of dnj-14 phenotypes is undiminished by sir–2.1 mutation demonstrates that SIR-
2.1 activation is not essential for all resveratrol effects, in contrast with some (32-34) but 
not all (41) C. elegans studies.  
The dnj-14 model could shed light on the mechanism of action of resveratrol and, 
indeed, our observation that rolipram mimics the effect of resveratrol in rescuing dnj-14 
mutants is consistent with the recent discovery that resveratrol is an inhibitor of cAMP 
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phosphodiesterases (31). Rolipram, like resveratrol, has cardioprotective and anti-
inflammatory properties and has been shown to be neuroprotective in animal models of 
Alzheimer’s disease and axonal degeneration (42, 43). Interestingly, acute application of 
forskolin, which increases cAMP levels by activation of adenylate cyclase rather than 
phosphodiesterase inhibition, can ameliorate the neuromuscular transmission defects in 
mouse dnajc5 null mutants (44). Given that misfolding of SNAP-25 and hence reduced 
SNARE complex formation are thought to be the downstream consequence of impaired 
CSP function (18, 19), it may be that resveratrol and rolipram compensate for this by 
activating alternative pathways resulting in improved SNARE complex formation, as 
seen with synuclein overexpression and proteasome inhibition (5, 17). Indeed, 
phosphorylation of SNAP-25 and other synaptic exocytosis proteins by cAMP-dependent 
protein kinase is known to increase the pool of releasable synaptic vesicles, resulting in 
greater SNARE-dependent neurotransmission (45). However, as attempts to measure 
cAMP increases by resveratrol and rolipram in worms were unsuccessful, we cannot rule 
out the possibility that rescue of the dnj-14 mutant phenotypes by these compounds 
occurs via alternative mechanisms that are independent of cAMP. Nevertheless, the 
observation that treatment with resveratrol can mitigate the loss of CSP function in a 
Sirtuin-independent manner suggests that this may be a therapeutic strategy for patients 
with ANCL and potentially other neurodegenerative diseases.  
 
 
 
 
 16 
MATERIALS AND METHODS  
Materials 
C. elegans strains RM2754 dnj-14(ok237), GR1373 eri-1(mg366) and VC199 sir-
2.1(ok434) were obtained from the Caenorhabditis Genetics Center (CGC; University of 
Minnesota, Twin Cities, MN, USA). The TM3223 dnj-14(tm3223) strain was obtained 
from the National Bioresource Project for the Experimental Animal “Nematode C. 
elegans” based in the lab of Dr Shohei Mitani (Tokyo Women’s Medical University, 
Tokyo, Japan). The dnj-14 RNAi plasmid was obtained from Gene Service (Cambridge, 
UK).  The pRAB100 and pPD117.01 plasmids were gifts from Drs. Michael Nonet 
(Washington University, USA) and Andrew Fire (Stanford University, USA), 
respectively. All other materials were from Sigma (Poole, UK) unless stated otherwise. 
 
Strain construction and verification 
Transgenic strains were generated by germline injection of expression constructs (5-20 
ng/μl) as previously described (46). To visualise neurons, strains were injected with 
pRAB100, which carries GFP under the control of the pan-neuronal rab-3 promoter (47). 
For transgenic rescue experiments, a construct comprising the genomic coding region of 
dnj-14 plus 560 bp of upstream flanking sequence was inserted into a pPD117.01 plasmid 
with the GFP-coding region removed. Outcrossing was performed by mating with the 
wild type N2 strain. The ok237 strain was outcrossed 6 times and the tm3223 strain 
outcrossed 5 times. The double mutant AMG74 dnj-14(tm3223);sir-2.1(ok434) strain was 
created by mating the outcrossed TM3223 dnj-14(tm3223) strain with the VC199 sir-
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2.1(ok434) strain and selecting for stable homozygous double mutant progeny. Strain 
genotypes were verified by single worm PCR analysis using the following primers:  
 
No. Primer Name Sequence 5’ – 3’ 
1 dnj-14 del rev TGCTCTCAACAGACCCATAC 
2 dnj-14 del mid fwd ATTCGCACGATCCGAAAAAG 
3 dnj-14 del full fwd CTGCATAGGGCACTCCTAGAAAT 
4 tm3223 del full fwd GCTTGTCTTACCTTATGTCGTCG 
5 sir-2.1 del rev CAGATAGTTCATACTGAAAATCT 
6 sir-2.1 del fwd AATCCCAATTGAACTCGCTG 
 
Nematode Culture  
C. elegans were grown under standard conditions on nematode growth media (NGM; 2% 
(w/v) agar, 0.3% (w/v) NaCl, 0.25% (w/v) peptone, 1 mM CaCl2, 5 μg ml-1 cholesterol, 
25 mM KH2PO4, 1 mM MgSO4) agar plates. Escherichia coli OP50 was used as a food 
source; except for RNAi experiments, where the E. coli strain HT115 carrying the pG-
L4440 vector was used. The wild type reference strain was Bristol N2 except for RNAi 
experiments, where the eri-1 hypersensitive strain was used. All strains were cultured and 
assays performed at 20ºC. 
 
RNAi experiments 
NGM plates containing 25 μg/ml carbenicillin and 1 mM IPTG were seeded with 
transformed HT115 bacteria and allowed to induce overnight. L3-L4 stage worms were 
transferred to each plate and once the next generation of worms had reached young adult 
stage, three adults were moved onto individual replica plates, allowed to lay eggs and 
removed the following day.  These progeny were used in the assays once they had 
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reached adulthood. To determine the extent of RNAi-mediated knockdown of dnj-14 
expression, worms were harvested after three days on RNAi or control plates. Total RNA 
was extracted using TRIzol (Invitrogen, UK) and equal amounts of RNA (1μg) were 
incubated with reverse transcriptase and random hexamers (Promega, UK) to generate 
first-strand cDNA. This cDNA was amplified by PCR using primers for dnj-14, or for the 
β-actin gene, act-1, as control.   
 
Locomotion assays 
Locomotion was measured in solution and quantified as thrashes per minute (one thrash 
defined as one complete sinusoidal movement from maximum to minimum amplitude 
and back again), as previously described (46). Single hermaphrodites were removed from 
NGM plates and placed in a Petri dish containing 200 μl freshly made Dent’s solution 
(140 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4 with 
bovine serum albumin at 0.1 mg/ml). Assessment of locomotion was performed 10 
minutes following immersion in solution. At least 10 animals were recorded per strain 
tested per experiment.  
 
Aldicarb assays 
Acute sensitivity to aldicarb was assessed by measuring time to onset of paralysis 
following exposure to the drug, as previously described (26, 48, 49). For each experiment 
20-30 animals were placed onto the centre of an unseeded NGM plate containing 1 mM 
aldicarb. To assess paralysis worms were lightly mechanically stimulated every 5-10 
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minutes following drug exposure. Worms were scored as paralysed when they failed to 
respond to stimulation and pharyngeal pumping had ceased. 
 
Lifespan assays  
Prior to lifespan analysis, worms were synchronised either by bleaching or by timed egg 
laying. Worms were then cleaned twice by washing in M9 buffer (5 g l-1 NaCl, 3 g l-1 
KH2PO4, 6 g l-1 Na2HPO4, 1 mM MgSO4) for 10 minutes each before picking onto 
lifespan plates. Worms were picked onto fresh plates every alternate day to remove 
progeny, and were then checked for survival until all worms on the plates were dead. 
Worms were scored as dead when they failed to respond to mechanical stimulation from 
a tungsten wire or when pharyngeal pumping had ceased. At least 25 worms were used in 
each lifespan assay and all lifespan assays were repeated at least twice. 
 
Food race and chemotaxis assays 
Food race assays were based on a previously described method (50).  Briefly, NGM 
plates were poured three days prior to use on 60-mm petri dishes. They were seeded with 
30 μl OP50 10 mm from the edge of the plate. 20-30 age-synchronised worms were then 
washed twice in M9 buffer and placed 10 mm from the edge opposite to the food. The 
number of worms on the food was recorded, and those animals removed, every 10 
minutes for two hours. Chemotaxis assays were based on a previously described method 
(51).  Briefly, plates were made three days prior to use on 100-mm petri dishes 
containing 2% (w/v) agar, 5 mM KH2PO4, 1 mM CaCl2, 1 mM MgSO4. Worms were 
washed in M9 buffer and placed on the centre of the plate. One microlitre of the attractant 
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and the diluent (ethanol) were pipetted on opposite edges of the plate. The number of 
worms on either side of the plate was counted after 90 minutes. The Chemotaxis Index 
was calculated as CI=(number of worms at attractant – number of worms at control)/total 
number of worms. A value of CI=0.11 was considered as baseline for false positives, as 
previously established (51).  
 
Microscopy 
Worms were age synchronised and divided into age groups of young (< 7 days), middle-
aged (9-12 days) and old (> 12 days). Animals were immobilised in a solution of 20:20 
PEG:Glycerol in PBS and imaged on a Nikon Eclipse Ti S fluorescence microscope with 
a 20X objective and processed using the software NIS Elements. The neurodegeneration 
phenotype was classified based on altered neuronal GFP fluorescence as a) loss of 
neuronal cell bodies, a reduction in the number of visible neurites, or the presence of 
contorted neuronal processes in the head of the worms, or b) appearance of large 
fluorescent punctae within the dorsal nerve cord. The presence or absence of these 
phenotypes was used as a scoring system to quantify the phenotype. 
 
Drug treatment 
Individual compounds were dissolved in PBS, DMSO or ethanol and then added to 
molten NGM agar before pouring into petri dishes. Control NGM plates contained the 
appropriate dilution of vehicle. For the lifespan screen, all plates contained FUDR to 
prevent progeny overgrowth. Plates were allowed to dry for 1-2 days before seeding with 
OP50 bacteria. Developmentally synchronised worms prepared as described above were 
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transferred onto the drug plates at L4 stage. For lifespan and neurodegeneration assays, 
worms were imaged for GFP fluorescence and assessed for viability every two days, and 
were transferred to fresh chemical plates as required. For food race and chemotaxis 
assays, resveratrol and rolipram were added to all media, including M9 washing buffers 
and assay plates. 
 
Cyclic AMP assay 
This was based on a previously published method (52) using a commercial cAMP ELISA 
kit (GE Healthcare). Worms were synchronised by bleaching and grown on NGM plates 
seeded with JB1669 adenylyl cyclase deficient bacteria (Genotype: JB1669 F- 
glnV44(AS) recA1 endA1 gyrA96(NalR) thi1 hsdR17 spoT1 rfbD1 cyaA). 
Approximately fifteen 60-mm plates of day 2 worms were washed off into M9 solution. 
The worms were allowed to settle, supernatant removed and washed again in 10 ml M9 
buffer. This was repeated a further 2 times. After removing the supernatant the worms 
were made up to a final volume of 3 ml and split into three eppendorfs (1ml per tube). 
These worms were treated with vehicle control (ethanol), resveratrol or rolipram for up to 
2 hours at room temperature on a rocker. The worms were then pelleted and the 
supernatant reduced to 100 µl. To this, 350 µl of M9 buffer was added plus 50 µl of Lysis 
Reagent 1A from the cAMP assay kit. Worms were vortexed for 30 seconds, sonicated 
three times for 9 seconds, and vortexed again. The samples were centrifuged to pellet any 
debris and the supernatant removed for use in the ELISA and for protein estimation. 
Samples were both used straight or diluted 1 in 2. Cyclic AMP concentrations were 
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determined by ELISA following the manufacturer’s instructions and normalised for 
protein concentration. 
 
 
Mechanosensation and pharyngeal pumping assays  
Prior to assays, worms were synchronised and grown on NGM plates seeded with OP50 
bacteria until 6-days old. Mechanosensation  assays  were based on a previously 
described method (53). A male eyelash was plucked and the root end of this was glued to 
a toothpick, leaving the tapered end free. Before assaying, this was sterilized by dipping 
in 70% ethanol and subsequently air-dried. The worms were then transferred on to an 
unseeded 35mm plate and left for five minutes to acclimatise. Mechanosensation was 
assessed by gently touching the eyelash to the side of the worm’s head at a perpendicular 
angle. Each worm was assayed ten times  and  the  number  of  times  the  worm  either  
stopped  or  reversed  its direction of movement was recorded.  For pharyngeal pumping 
assays, worms feeding on OP50 bacteria were observed under x80 magnification using a 
stereomicroscope. The number of contraction/relaxation cycles or pumps per thirty 
seconds was then counted for each worm.   
  
Statistical analysis 
Statistical significance was assessed using Students’ t-tests for behavioural assays. Log-
rank tests were employed for aldicarb and lifespan assays, using the OASIS online 
service (54). 
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FIGURE LEGENDS 
 
FIG. 1: Phenotypic analysis of dnj-14(ok237) mutants.  
(A) dnj-14 mutants have a short lifespan. Data shown are pooled from 7 independent 
lifespan assays comparing synchronised wild type (Bristol N2) and dnj-14(ok237) strains 
(n=230 and 213 worms, respectively). 
(B) dnj-14 mutants have a minor locomotion defect. The rate of thrashing in solution was 
measured in animals of the indicated age ranges after synchronisation. Data are shown as 
mean ± SEM from 2 independent assays (n=20-50 worms of each strain per time point; 
*P<0.05). 
(C,D) dnj-14 mutants have a minor, age-dependent neurotransmission defect. The time 
taken for paralysis to be induced by aldicarb was not significantly different from N2 
controls in 1-day-old dnj-14 mutants (C), but was significantly delayed in 5-day-old (D) 
animals. Data shown are pooled from 3 independent assays (n=60 worms for each strain). 
(E) Out-crossed dnj-14 mutants retain a short lifespan. The dnj-14(ok237) strain was out-
crossed 6 times with the wild type N2 strain and then lifespan analysis performed. Data 
shown are pooled from 3 independent lifespan assays comparing synchronised out-
crossed (OC) and non-out-crossed strains (n=68-74 worms for each strain). 
(F) The short lifespan of the dnj-14 strain can be rescued by a dnj-14 transgene. A 
construct containing the coding region and putative upstream promoter of the dnj-14 gene 
was injected into dnj-14(ok237) worms and then lifespan analysis performed. Data shown 
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are from a single lifespan assay (n=40, 32, 34 and 26 worms for untransformed, rescue 1, 
rescue 2 and rescue 3 strains, respectively). 
 
FIG. 2: Multiple dnj-14 alleles and RNAi produce similar phenotypes. 
(A) dnj-14(tm3223) mutants have a short lifespan. Data shown are pooled from 4 
independent lifespan assays comparing synchronised wild type (N2) and dnj-14(tm3223) 
strains (n=113 and 144 worms, respectively). 
(B) Distinct dnj-14 alleles produce a similar small locomotion defect. The rate of 
thrashing in solution was measured in 5-day old animals. Data are shown as mean ± SEM 
from 2 independent assays (n=35 worms for each strain; *P<0.05). 
(C) Distinct dnj-14 alleles produce a similar small neurotransmission defect. The time 
taken for paralysis to be induced by aldicarb was measured in 5-day-old animals. Data 
shown are pooled from 2 independent assays (n=41, 49 and 45 worms for N2, ok237 and 
tm3223 strains, respectively). 
(D) RNAi of dnj-14 shortens lifespan. RNAi sensitive eri-1 strains were maintained on 
control NGM plates or plates containing bacteria harbouring a dnj-14 RNAi feeding 
plasmid. Data shown are pooled from 2 independent lifespan assays (n=86 and 101 
worms for control and dnj-14 RNAi, respectively). 
(E) RNAi of dnj-14 causes a small locomotion defect. The rate of thrashing in solution of 
eri-1 worms was measured in control or RNAi-treated animals of the indicated ages. Data 
are shown as mean ± SEM from individual assays (n=15 worms of each strain per age-
point; *P<0.05). 
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(F) Validation of RNAi knockdown. RNA was prepared from eri-1 worms (control and 
RNAi-treated) and used to generate cDNA for subsequent RT-PCR amplification using 
primers specific for dnj-14 and act-1.  
 
FIG. 3: Age-dependent sensory neuron impairment in dnj-14 mutants.  
(A) Neurodegeneration in dnj-14(ok237) mutants. Worms were injected with a rab-3-
promoter-driven GFP construct to visualise all neurons, synchronised and grown for at 
least 9 days and then immobilised for GFP imaging. Representative images of the loss of 
cell bodies and processes in the head region (neuron loss) and the presence of large 
fluorescent aggregates in the dorsal nerve cord (punctae) that were typically observed are 
shown. Scale bar 50 µm. 
(B) Food sensing defect in dnj-14 mutants. The time taken for wild type and dnj-
14(tm3223) worms of the indicated age to move to a bacterial food source was measured. 
Data shown are from individual assays, using 22-26 worms of each strain per age-point. 
(C) Transgenic rescue of the dnj-14 food sensing defect. The time taken to move to a 
bacterial food source was measured in 6-day-old wild type, dnj-14(ok237) and dnj-
14(ok237) rescue strains (the latter containing an extrachromosomal dnj-14 transgene). 
Data shown are pooled from 2 independent assays (n=54-65 worms per strain). 
(D) Chemotaxis defect in dnj-14 mutants. The proportion of wild type and dnj-
14(tm3223) worms that had moved to the attractant, isoamyl alcohol, within 90 min was 
measured in 2-day-old animals. Data shown are pooled from 6 independent assays 
(n=168-170 worms of each strain; *P<0.05). 
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FIG. 4: Resveratrol rescues dnj-14 mutant phenotypes.  
(A) Drug screen for compounds able to increase the short lifespan of dnj-14 mutants 
identifies resveratrol. dnj-14(ok237) worms were grown from L4 stage on NGM plates 
containing the indicated compounds or appropriate vehicle controls. Data shown are 
pooled from 2 independent lifespan assays (n=67 to 115 worms used per condition). 
(B,C) Concentration-dependency of resveratrol. dnj-14(ok237) worms were grown from 
L4 stage on NGM plates containing the indicated concentrations of resveratrol. Data 
shown are derived from a single lifespan assay using 21-25 worms for each drug 
concentration and are displayed as raw survival curves (B) and as mean lifespans (C). 
(D) Resveratrol rescues the dnj-14 food sensing defect. The time taken for 6-day-old N2 
and dnj-14(tm3223) worms grown in the absence or presence of 100 µM resveratrol to 
move to a bacterial food source was measured. Data shown are pooled from 2 
independent assays (n=42 to 47 worms per strain per condition). 
(E) Resveratrol rescues the dnj-14 chemotaxis defect. The proportion of wild type and 
dnj-14(tm3223) worms that had moved to the attractant, isoamyl alcohol, within 90 min 
was measured in 2-day-old animals grown in the absence or presence of 100 µM 
resveratrol. Data shown are pooled from 3 independent assays (n=85-102 worms per 
strain per condition; *P<0.05). 
 
FIG. 5: Resveratrol activity is mimicked by phosphodiesterase inhibition and is 
independent of SIR-2.1. 
 36 
(A) Rolipram, a cAMP phosphodiesterase inhibitor, rescues the short lifespan of dnj-14 
mutants. N2 or dnj-14(tm3223) worms were grown from L4 stage on NGM plates 
containing 100 µM rolipram or vehicle control. Data shown are pooled from 2 
independent lifespan assays (n=45-50 worms per condition). 
(B) Rolipram rescues the dnj-14 food sensing defect. The time taken for 6-day-old N2 
and dnj-14(tm3223) worms grown on NGM plates in the absence or presence of 100 µM 
rolipram to move to a bacterial food source was measured. Data shown are pooled from 2 
independent assays (n=47-52 worms per condition). 
 (C) Rolipram rescues the dnj-14 chemotaxis defect. The proportion of wild type and dnj-
14(tm3223) worms that had moved to the attractant, isoamyl alcohol, within 90 min was 
measured in 2-6-day-old animals grown in the absence or presence of 100 µM rolipram. 
Data shown are pooled from 5 independent assays (n=151-160 worms per condition; 
*P<0.05). 
(D-F) Effect of resveratrol on lifespan of dnj-14 and sir-2.1 mutants. Worms of the 
indicated genotypes were grown from L4 stage in the absence (D) or presence (E,F) of 
100 µM resveratrol. Data shown are pooled from 2 independent lifespan assays 
comparing synchronised single and double mutant animals using 46-50 worms for each 
strain/condition. 
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Supplementary Information 
 
Supplementary Table 
Compound Suggested Mechanisms Assay Reference 
    
Resveratrol Sirtuin activator, PDE 
inhibitor, antioxidant 
Worm PolyQ neuroprotection 
Mouse amyloid plaque reduction 
(1) 
(2) 
    
Mithramycin 
  
 
DNA binding agent Worm PolyQ neuroprotection 
Mouse HD survival 
(3) 
(4) 
    
Clioquinol Metal chelator and 
CLK-1 inhibitor 
Worm clk-1 partial mimic 
Mouse Alzheimer cognition  
(5) 
(6) 
    
Valproic acid Anticonvulsant  
(HDAC inhibitor) 
Worm lifespan increase 
Fly PolyQ neuroprotection 
(7) 
(8) 
    
Mianserin Antidepressant 
(5-HT2 blocker) 
Worm lifespan increase (9) 
    
C2–8 
 
unknown Fly PolyQ neuroprotection 
Mouse HD survival 
(10) 
(11) 
    
Rapamycin mTOR inhibitor Cell synuclein/PolyQ 
Mouse AD cognition 
(12) 
(13) 
 
Table S1: Compounds used in dnj-14 lifespan screen. 
 
Figure legends 
 
FIG. S1: dnj-14 gene structure, mutations and homology to human dnajc5.  
(A) Sequence alignment of the predicted products of the human DNAJC5 and C. elegans dnj-
14a genes (CSPα and DNJ-14 proteins, respectively). 
(B) Exon structure of the dnj-14 gene and location of the ok237 and tm3223 alleles. 
(C) Confirmation of the ok327 deletion. Genomic DNA from wild type N2 and dnj-14(ok237) 
worms was amplified using primers flanking the deletion (left panel) or with one flanking 
primer and a primer within exon 2 of dnj-14 (right panel). 
(D) Characterisation of the tm3223 insertion/deletion. Genomic DNA from wild type N2 and 
dnj-14(tm3223) worms was amplified using primers flanking the mutation site.  
 
FIG. S2: Quantification of neurodegeneration in dnj-14(ok237) mutants.  
Wild type N2 and dnj-14(ok237) worms were synchronised and grown on NGM plates 
containing vehicle control (ethanol) or 100 µM resveratrol for at least 9 days. Animals were 
then immobilised for GFP imaging and scored for head neuron abnormalities (‘neuron loss’) 
based on loss of neuronal cell bodies, a reduction in the number of visible neurites, or the 
presence of contorted neuronal processes in the head of the worms; and the presence of large 
fluorescent punctae in the dorsal nerve cord (‘punctae’). The number of worms analysed was 
45 for N2, 35 for dnj-14 and 20 for dnj-14 Resveratrol. 
 
FIG. S3: Visualisation of neurodegeneration in dnj-14(ok237) mutants.  
Wild type N2 and dnj-14(ok237) worms were synchronised and grown on NGM plates for at 
least 9 days. Animals were then immobilised for GFP imaging. Typical images are shown for 
various animals. These illustrate the loss of neuronal cell bodies, reduction in the number of 
visible neurites, or the presence of contorted neuronal processes in the head of the worms that 
was frequently seen in dnj-14 mutants. In contrast, age-matched wild type N2 animals 
generally exhibited obvious neuronal cell bodies and had clearly labelled multiple neurites 
that extended straight to the end of the worm’s head without twisting.  
 
FIG. S4: Mechanosensation is unaffected in aged dnj-14 mutants.  
Wild type N2, dnj-14(tm3223) and dnj-14(ok237) worms were synchronised and grown on 
NGM plates until 6 days of age. After transfer to unseeded plates, mechanosensation was 
assessed by gently touching an eyelash to the side of the worm’s head at a perpendicular 
angle. Each worm was assayed ten times  and  the  number  of  times  the  worm  either  
stopped  or  reversed  its direction of movement was recorded. No significant differences 
between wild type and dnj-14 mutants were seen (n=15 animals per strain). 
 
FIG. S5: Pharyngeal pumping is unaffected in aged dnj-14 mutants.  
Wild type N2, dnj-14(tm3223) and dnj-14(ok237) worms were synchronised and grown on 
NGM plates until 6 days of age. After transfer to plates freshly seeded with OP50 bacteria, 
the number of contraction/relaxation cycles of the pharynx per thirty seconds was for each 
worm was recorded. No significant differences between wild type and dnj-14 mutants were 
seen (n=15 animals per strain). 
 
FIG. S6: Measurement of cAMP levels in worms treated with resveratrol and rolipram.  
Wild type N2 worms were age-synchronised and grown on 60-mm NGM plates seeded with 
JB1669 adenylyl cyclase deficient bacteria. Approximately fifteen such plates of day 2 
worms were washed in M9 buffer and then treated in M9 buffer containing vehicle control 
(ethanol), 100 µM resveratrol or 100 µM rolipram for 120 mins. The worms were then lysed, 
centrifuged to pellet any debris, and the supernatant used immediately for assay. Endogenous 
cyclic AMP levels were measured by ELISA and normalised to total protein concentration. 
Data shown are mean + SEM (n = 4 biological replicates). No significant differences between 
treatments were seen (n=15 animals per strain). 
 
MOVIE S1: Superficially normal locomotion in dnj-14(ok237) mutants  
The movement of worms on NGM agar plates was recorded. Wild type N2 worms are shown 
first, followed by dnj-14(ok237) mutants.  
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